Acute Heart Failure (AHF) Therapeutics Market - Robust Pipeline Of Drugs Over The Forecast Period 2018-2026 | Explore By Global Key Players Pfizer Inc., Bayer AG, Novartis AG, Merck & Company, Inc., Amgen Inc., Cardiorentis AG, Cytokinetics, Inc.

Acute heart failure (AHF) is a progressive condition, in which, the heart muscle is unable to pump enough blood through the heart to meet body’ optimal blood and oxygen level. Congestive heart failure is type of heart failure which requires timely medical attention. Moreover, distinguish between acute and chronic heart failure is important from a clinical standpoint, on which further medication depends. For this, N terminal proB-type natriuretic peptide levels are used for distinguishing acute versus chronic left ventricular dysfunction. An elevated levels of natriuretic peptide were present in patients with acute heart failure compared to those with chronic heart failure patient.

Heart failure symptoms vary widely from person to person, depending on types of heart failure patient. The main symptoms of heart failure are caused due to fluid accumulation or congestion and poor blood flow to the body. Symptoms caused by fluid accumulation or congestion includes shortness of breath, weight gain, coughing, swollen ankles, legs or abdomen, while dizziness, rapid heart rate, and fatigue are symptoms associated with reduced blood flow to parts of the body.

Get FREE In-Depth Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/1910

Acute Heart Failure (AHF) Therapeutics Market – Competitive Landscape

Some of the key players in this market are

1. Novartis AG
2. Cardiorentis AG
3. Bristol-Myers Squibb Company
4. Amgen Inc.
5. Bayer AG
6. Cytokinetics, Inc.
7. Merck & Company, Inc.
8. Ono Pharmaceutical Co., Ltd.
9. Pfizer Inc.,

among others.....

Key players in the marker are engaged in development of new drugs for acute heart failure (AHF). These players are incorporating collaboration strategies to remain competitive in the market.

Acute Heart Failure (AHF) Therapeutics Market – Drivers

The global acute heart failure therapeutics market is expected to witness significant growth due to approval of new drugs. For instance, in July 2015, Novartis received U.S. Food and Drug Administration (FDA) approval for their Entresto(TM) (sacubitril/valsartan) tablets on the treatment of heart failure with reduced ejection fraction. Entresto is indicated to reduce the risk of cardiovascular death and heart failure hospitalization.

Furthermore, robust pipeline of drugs over the forecast period (2018-2026), is another factor driving growth of acute heart failure therapeutics market. For instance, in March 2017, Cardioxyl Pharmaceuticals’ CXL-1427: a novel nitroxyl (HNO) donor (prodrug), which now operates under the Bristol-Myers Squibb Company (after Cardioxyl Pharmaceuticals’ acquisition by Bristol-Myers Squibb in December 2015); is present in Phase 2 clinical development phase. CXL-1427 is indicated to use as an intravenous treatment for acute decompensated heart failure (ADHF). Successful completion and further launch of Bristol-Myers Squibb’s innovative drug in future, will help to boost the acute heart failure (AHF) therapeutics market growth during the forecast period.

Acute Heart Failure (AHF) Therapeutics Market – Regional Analysis

Geographically, the market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America is expected to hold dominant position in global acute heart failure (AHF) therapeutics market, due to high prevalence of acute heart failure cases, in this region. For instance, according to Centers for Disease Control and Prevention (CDC), June 2016, around 5.7 million adults in the U.S. suffered from heart failure, in 2016. Moreover, about half of the people who develop heart failure die within 5 years of diagnosis.

Acute Heart Failure (AHF) Therapeutics Market – Taxonomy

By Disorder Type:

Right-sided Heart Failure
Left-sided Heart Failure: Systolic Failure, Diastolic Failure
Congestive Heart Failure

By Drug Category:

Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril (Capoten), Enalapril (Vasotec), Fosinopril (Monopril), Lisinopril (Prinivil, Zestril), Perindopril (Aceon), Quinapril (Accupril), Ramipril (Altace), Others

Angiotensin II Receptor Blockers: Candesartan (Atacand), Losartan (Cozaar), Valsartan (Diovan)

Angiotensin-Receptor Neprilysin Inhibitors (ARNIs): Sacubitril/valsartan

If Channel Blocker: Ivabradine (Corlanor)

Beta Blockers: Bisoprolol (Zebeta), Metoprolol Succinate (Toprol XL), Carvedilol (Coreg), Others

Aldosterone Antagonists: Spironolactone (Aldactone), Eplerenone (Inspra), Diuretics, Furosemide (Lasix), Bumetanide (Bumex), Torsemide (Demadex), Chlorothiazide (Diuril)

Amiloride (Midamor Chlorthalidone (Hygroton): Hydrochlorothiazide or HCTZ (Esidrix, Hydrodiuril), Others

Anticoagulants (Blood Thinners): Cholesterol Lowering Drugs (Statins), Digoxin

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America
Latin America
Europe
Asia Pacific
Middle East
Africa

Request For Customization of This Exclusive Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/1910

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.